期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

鞘氨醇-1-磷酸在肝纤维化研究中的进展 被引量：2

Progress of Sphingosine-1-Phosphate in the Pathogenesis of Liver Fibrosis
原文传递
导出
摘要 目的对近年来关于鞘氨醇-1-磷酸(sphingosine-1-phosphate,S1P)在肝纤维化中的作用及相关机制的研究做整理分析。方法查阅近年来的国内外文献,进行全面综合、整理和归纳。结果鞘氨醇-1-磷酸是一种具有生物活性的溶血磷脂,对肝纤维化的发生、发展和转归具有双重效应,这主要取决于其作用位点的不同。结论鞘氨醇-1-磷酸在肝纤维化治疗中具有重要的作用,但作用机制复杂,有待更深入的研究。 OBJECTIVE To analyze recent studies on the role of the sphingosine-1-phosphate （S1P） in liver fibrosis and related mechanism. METHODS By heading domestic and international documents in recent years. A comprehensive integrated progress was concluded. RESULTS S1P is a bioactive lysopholipid, studies show that S1P had a double effect on the development and regression of liver fibrosis, which mainly depended on its site of action. CONCLUSION S1 P plays an important role in the treatment of liver fi- brosis. But for its complex mechanism of action, further research need to be studied.
作者 陈连云 金欢欢 陈琴 张峰 陆茵 郑仕中
机构地区 南京中医药大学药理教研室 江苏省中药药效与安全性评价重点实验室
出处 《中国药学杂志》 CAS CSCD 北大核心 2014年第15期1281-1284,共4页 Chinese Pharmaceutical Journal
基金 国家自然科学基金资助项目(81270514 30873424) 教育部博士点基金项目(20103237110010) 江苏省六大人才基金(2009-B-010) 江苏高校优势学科建设工程资助项目(ysxk-2010) 南京中医药大学中药学一级学科开放课题资助项目(2011ZYX4-008) 十一五科技支撑计划(2008BAI51B02) 江苏省2013年度普通高校研究生科研创新新计划项目(CXZZ13-06)
关键词 鞘氨醇-1-磷酸 肝纤维化 肝星状细胞 机制研究 sphingosine-1 -phosphate liver fibrosis hepatic stellate cell mechanism research
分类号 R965 [医药卫生—药理学]
  • 相关文献

参考文献1

二级参考文献12

  • 1陈玮,陈维雄,陆允敏,陈金联,姚惠香.川芎嗪干预大鼠实验性肝纤维化的研究[J].世界临床药物,2007,28(9):522-525. 被引量：15
  • 2ISSA H,WILLIAMS E,TRIM N,et al.Apoptosis of hepaticstellate cells:Involvement in resolution of biliary fibrosis andregulation by soluble growth factors[J].Gut,2001,48(4):548-557.
  • 3BENYON R C,IREDALE J P.Is liver fibrosis reversible[J].Gut,2000,46(4):443-446.
  • 4MURPHY F R,ISSA R,ZHOU X Y,et al Inhibition of ap-optosis of activated hepatic stellate cells by tissue inhibitor ofmetalloproteinase-1 is mediated via effects on matrix metallo-proteinase inhibition[J].7 Biol Chem,2002,277(13):11069-11076.
  • 5SUKADA S,PARSONS C J,RIPPE R A.Mechanisms of liverfibrosis[J].Clin Chim Acta,2006,364(1-2);33-60.
  • 6FRIEDMAN S L.Mechanisms of disease:Mechanisms of hepaticfibrosis and therapeutic implications[J].Nat Clin Prac Gastro-enterol Hepatol,2004,1(2):98-105.
  • 7KISSELEVA T,BRENNER D A.Role of hepatic stellate cells infibrogenesis and the reversal of fibrosis[J].J Gastroenterol Hepa-tol,2007,22(1):73-78.
  • 8PARSONS C J,TAKASHIMA M,RIPPE R A.Molecular mecha-nisms of hepatic fibrogenesis[J].J Gastroenterol Hepatol,2007,22(SI):79-84.
  • 9Al W M.New Progress on study of antagonizing liver fibrosis[J].中国药学杂志,2008,43(3):161-164.
  • 10JI C W,LIU J M,LI L C.Effects of tetramethylpyrazine on pro-hibiting hepatic fibrosis in rats[J].中国药学杂志,2003,34(4):293-295.

共引文献1

同被引文献19

  • 1HERNANDEZ-GEA V, FRIEDMAN S L. Pathogenesis of liver fibrosis[J]. Annu Rev Pathol, 2011,28(6): 425-456.
  • 2SANCHEZ-VALLE V, CHAVEZ-TAPIA N C, URIBE M, et al. Role of oxidative stress and molecular changes in liver fibrosis: A review[J]. Curr Med Chem, 2012, 19(28): 4850-4860.
  • 3COMPORTI M, AREZZINI B, SIGNORINI C, et al. Oxidative stress, isoprostanes and hepatic fibrosis[J]. Histol Histopathol, 2009, 24(7):893-900.
  • 4POPOV Y, SCHUPPAN D. Targeting liver fibrosis: Strategies for development and validation of antifibrotic therapies[J]. Hepatology, 2009, 50(4): 1294-1306.
  • 5HOSONO-FUKAO T, HOSONO T, SEKI T, et al. Diallyltrisulfide protects rats from carbon tetrachloride-induced liver injury[J]. J Nutr, 2009, 139(12): 2252-2256.
  • 6ZENG T, ZHANG C L, ZHU Z P, et al. Diallyltrisulfide (DATS) effectively attenuated oxidative stress-mediated liver injury and hepatic mitochondrial dysfunction in acute ethanol-exposed mice[J]. Toxicology, 2008, 252(1-3):86-91.
  • 7FU Y, ZHENG S, LIN J, et al. Curcumin protects the rat liver from CCl4-caused injury and fibrogenesis by attenuating oxidative stress and suppressing inflammation[J]. Mol Pharmacol, 2008, 73(2):399-409.
  • 8NOVO E, PAROLA M. The role of redox mechanisms in hepatic chronic wound healing and fibrogenesis[J]. Fibrogenesis Tissue Repair, 2012, 5(suppl 1):S4.doi: 10.1186/1755-1536-5-S1-S4.
  • 9NORRIS E J, CULBERSON C R, NARASIMHAN S, et al. The liver as a central regulator of hydrogen sulfide[J]. Shock, 2011, 36(3): 242-250.
  • 10LI X, WANG X, HAN C, et al. Astragaloside IV suppresses collagen production of activated hepatic stellate cells via oxidative stress-mediated p38 MAPK pathway[J]. Free Radic Biol Med, 2013, 60: 168-176.

引证文献2

二级引证文献9

中国药学杂志
2014年 第15期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部